|
Synonyms: DANYELZA® | hu3F8 | naxitamab-gqgk
naxitamab is an approved drug (FDA (2020))
Compound class:
Antibody
Comment: Naxitamab (hu3F8) is a humanized monoclonal antibody that targets ganglioside GD2 that was developed by Y-mAbs Therapeutics for potential to treat high risk neuroblastoma [1-2]. GD2 is a sialised glycosphingolipid cell adhesion molecule, that is highly expressed on neuroectoderm-derived tumours and sarcomas, including neuroblastoma, retinoblastoma, melanoma and small cell lung cancer [7]. Naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumour cells [5].
Protein BLAST analysis of the peptide sequences of the heavy and light chains from the INN submission for naxitamab, show 100% matches with sequences in patent US10167341B2, which claims 'High affinity anti-GD2 antibodies' [4]. From sequence comparisons, naxitamab would appear to be referred to as hu3F8V1 in this patent. |
| Bioactivity Comments |
| Naxitamab (hu3F8V1) binds to GD2 in vitro (Biacore SPR assay) with a KD of 3 nM [4]. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
